REPLICATE® System | Updates

By Lea Ellermeier & Rüdger Rubbert

FDA simplifies admission process for REPLICATE's US market entry!


Dear Companists,

First, we would like to thank our 1800+ Companists who invested more than EUR 2.9 million together with the co-investment. We are looking forward to start into the year 2018 alongside all of you. In this report, we would like bring you up to speed and inform you of exciting developments.

Our utmost priority at present is penetrating the US market. The US regulatory authority FDA has been pursuing a strategy they call the “Least Burdensome Approach.” Its aim is to facilitate and accelerate the approval of modern technology. A new guideline was recently published in December 2017:

The FDA is currently re-educating its employees for the new procedures. This process is 90% complete.


For the REPLICATE® system, this means that we are still preparing our application for US market admission and that we are adjusting the necessary documents according to the new regulations. We are working in close cooperation with our US partners, who are supervising our application process, and expect that the admittance process will become less susceptible to bureaucratic imponderables as a result of the new regulations. This means that the market launch planned for mid-2018 is very probable.


Replicate Dental Technologies


We have also started preparing our marketing for the US market entry. An important milestone was the renaming of our US subsidiary, Natural Dental Implants Inc., to REPLICATE Dental Technology Inc. The renaming is part of our marketing strategy of strengthening the protected product name REPLICATE. At the same time, the new name clearly identifies us as a high-tech company in the field of dental medicine. The tech company label is of particular importance for valuation during the expected initial public offering. We also plan on renaming the NDI AG by mid-year.

We are very pleased with the FDA’s current strategy and look forward to the upcoming US market launch.


Kind regards,

Lea und Rüdger


Only registered Companists can comment. Please log in to leave a comment.


Investments in crowdfunding projects offer great opportunities, but they are risk investments. In the worst case, the entire investment amount may be lost. Consequently, these investments are unsuitable for retirement plans. However, there is no obligation to make further contributions. Investors can minimize their risk by splitting their investment amount between crowdfunding campaigns rather than investing all of it in one crowdfunding campaign. Professional investors often follow this strategy because it causes the risk to be distributed among several investments. In this way, successful investments can balance other less successful investments.

The shares of the Companists are subordinated profit-participating loans (partiarische Nachrangdarlehen). Such loans are shares in a business with similar characteristics as equity. If the company becomes insolvent or is liquidated, the claims of the Companists – just like those of all other shareholders of the company – will be satisfied from the assets in the insolvency or the assets in liquidation only after the claims of all other external creditors have been satisfied. Thus, Companists are treated like any other shareholder of the company during insolvency or liquidation proceedings.

The company information published on the Companisto website is provided solely by the companies. The projections made by the companies do not guarantee successful development of the company in the future. Consequently, crowdfunding investments are suitable only for those investors who can cope with the risk of a total loss of the capital invested. Investors make their own independent investment decisions and bear all risks themselves.

The investments are provided and issued by the individual companies. Companisto is neither the provider nor the issuer of the investments, but solely the internet service platform.

€ 3,500,000

Invested ( € 1M co-invested )



3.23 %

Share Offered

Please note
The acquisition of this asset involves considerable risks and can lead to the complete loss of the assets used.

Follow us

Contact Us
Your contact for all questions about investing on Companisto:
Sascha Jung
Investor Relations

Toll-free phone number for investors

0800 - 100 267 0 (DE)
0800 - 100 267(AT / CH)

Service hours Mo-Fr 9 a.m.- 7 p.m.

Companisto GmbH
Köpenicker Str. 154
10997 Berlin
Der E-Mail-Newsletter ist jederzeit mit einem Klick abbestellbar.
Source: Own research. Based on data from the German Private Equity and Venture Capital Association - BVK, among others.
Investor Support
Please register in order to see the complete profile of REPLICATE® System.
Already registered?    Log in